The role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of diffuse large b cell lymphoma: Update of the 2001 evidence-based review

Biology of Blood and Marrow Transplantation

Volumn 17, Issue 1, 2011, Pages 20-47.e30

  Oliansky, Denise M ^a   Czuczman, Myron ^a   Fisher, Richard I ^b   Irwin, Frank D ^c   Lazarus, Hillard M ^d   Omel, James ^e   Vose, Julie ^f   Wolff, Steven N ^g   Jones, Roy B ^h   McCarthy Jr , Philip L ^a   Hahn, Theresa ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^c OPTUM   (United States)

^d UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^e Independent Patient Advocate   (United States)

^f UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^g MEHARRY MEDICAL COLLEGE   (United States)

^h UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Adult; Diffuse large B cell lymphoma; Hematopoietic stem cell transplantation; Systematic evidencebased review; Therapy

Indexed keywords

BLEOMYCIN; BORTEZOMIB; BUSULFAN; CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; GROWTH FACTOR; IFOSFAMIDE; LENALIDOMIDE; MELPHALAN; METHOTREXATE; MITOXANTRONE; PREDNISONE; RITUXIMAB; TENIPOSIDE; TOSITUMOMAB; VINCRISTINE; VINDESINE; VORINOSTAT; CYTOTOXIN;

ALLOGENEIC STEM CELL TRANSPLANTATION; AUTOLOGOUS STEM CELL TRANSPLANTATION; BONE MARROW; BONE MARROW TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER RELAPSE; CANCER RISK; CANCER SURVIVAL; COMPARATIVE EFFECTIVENESS; DISEASE FREE SURVIVAL; DRUG MEGADOSE; EVENT FREE SURVIVAL; EVIDENCE BASED MEDICINE; EVIDENCE BASED REVIEW; GENE EXPRESSION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; LARGE CELL LYMPHOMA; NONHODGKIN LYMPHOMA; NONMYELOABLATIVE STEM CELL TRANSPLANTATION; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; REVIEW; SALVAGE THERAPY; STEM CELL TRANSPLANTATION; TREATMENT INDICATION; WHOLE BODY RADIATION; METHODOLOGY; MULTIMODALITY CANCER THERAPY; PRACTICE GUIDELINE;

COMBINED MODALITY THERAPY; CYTOTOXINS; EVIDENCE-BASED MEDICINE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; PRACTICE GUIDELINES AS TOPIC;

EID: 79956196646     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2010.07.008     Document Type: Review

References (82)

1. Hahn T, Wolff SN, Czuczman M, et al. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of diffuse large cell B-cell non-Hodgkin' lymphoma: a evidence-based review. Biol Blood Marrow Transplant. 2001;7: 308-331.
2. Greb A, Bohlius J, Trelle S, et al. High-dose chemotherapy with autologous stem cell support in first-line treatment of aggressive non-Hodgkin lymphoma: results of a comprehensive metaanalysis. Cancer Treat Rev. 2007;33:338-346.
3. Strehl J, Mey U, Glasmacher A, et al. High-dose chemotherapy followed by autologous stem cell transplantation as first-line therapy in aggressive non-Hodgkin's lymphoma: a meta-analysis. Haematologica. 2003;88:1304-1315.
4. Gisselbrecht C, Lepage E, Molina T, et al. Shortened first-line high-dose chemotherapy for patients with poor-prognosis aggressive lymphoma. J Clin Oncol. 2002;20:2472-2479.
5. Kaiser U, Uebelacker I, Abel U, et al. Randomized study to evaluate the use of high-dose therapy as part of primary treatment for "aggressive" lymphoma. J Clin Oncol. 2002;20:4413-4419.
6. Kluin-Nelemans HC, Zagonel V, Anastasopoulou A, et al. Standard chemotherapy with or without high-dose chemotherapy for aggressive non-Hodgkin lymphoma: randomized phase III EORTC Study. J Natl Cancer Inst. 2001;93:22-30.
7. Martelli M, Gherlinzoni F, De Renzo A, et al. Early autologous stem-cell transplantation versus conventional chemotherapy as front-line therapy in high-risk, aggressive non-Hodgkin lymphoma: an Italian multicenter randomized trial. J Clin Oncol. 2003;21:1255-1262.
8. Milpied N, Deconinck E, Gaillard F, et al. Initial treatment of aggressive lymphoma with high-dose chemotherapy and autologous stem-cell support. N Engl J Med. 2004;350:1287-1295.
9. Olivieri A, Santini G, Patti C, et al. Upfront high-dose sequential therapy (HDS) versus VACOP-B with or without HDS in aggressive non-Hodgkin lymphoma: long-term results by the NHLCSG. Ann Oncol. 2005;16:1941-1948.
10. Betticher D, Martinelli G, Radford J, et al. Sequential high dose chemotherapy as initial treatment for aggressive sub-types of Non-Hodgkin Lymphoma: results of the international randomized phase III trial (MISTRAL). Ann Oncol. 2006;17:1546-1552.
11. Vitolo U, Liberati AM, Cabras MG, et al. High dose sequential chemotherapy with autologous transplantation versus dose-dense chemotherapy MegaCEOP as first line treatment in poorprognosis diffuse large cell lymphoma: an "Intergruppo Italiano Linfomi" randomized trial. Haematologica. 2005;90:793-801.
12. Baldissera R, Nucci M, Vigorito A, et al. Frontline therapy with early intensification and autologous stem cell transplantation versus conventional chemotherapy in unselected high-risk, aggressive non-Hodgkin lymphoma patients: a prospective randomized GEMOH report. Acta Haematol. 2006;115:15-21.
13. Haioun C, Lepage E, Gisselbrecht C, et al. Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin lymphoma: final analysis of the prospective LNH87-2 Protocol-a Groupe d'Etude des Lymphomes de l'Adulte study. J Clin Oncol. 2000;18:3025-3030.
14. Haioun C, Lepage E, Gisselbrecht C, et al. Benefit of autologous bone marrow transplantation over sequential chemotherapy in poor-risk aggressive non-Hodgkin's lymphoma: updated results of the prospective study LNH87-2. Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol. 1997;15:1131-1137.
15. Haioun C, Lepage E, Gisselbrecht C, et al. Comparison of autologous bone marrow transplantation with sequential chemotherapy for intermediate-grade and high-grade non-Hodgkin's lymphoma in first complete remission: a study of 464 patients. Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol. 1994;12:2543-2551.
16. Santini G, Salvagno L, Leoni P, et al. VACOP-B versus VACOP-B plus autologous bone marrow transplantation for advanced diffuse non-Hodgkin's lymphoma: results of a prospective randomized trial by the non-Hodgkin's Lymphoma Cooperative Study Group. J Clin Oncol. 1998;16:2796-2802.
17. Gianni AM, Bregni M, Siena S, et al. High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma. N Engl J Med. 1997;336:1290-1298.
18. Verdonck LF, van Putten WLJ, Hagenbeek A, et al. Comparison of CHOP chemotherapy with autologous bone marrow transplantation for slowly responding patients with aggressive non-Hodgkin lymphoma. N Engl J Med. 1995;332:1045-1051.
19. Philip T, Guglielmi C, Hagenbeek A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin lymphoma. N Engl J Med. 1995;333:1540-1545.
20. Jantunen E, Canals C, Rambaldi A, et al. Autologous stem cell transplantation in elderly patients ($60 years) with diffuse large B-cell lymphoma: an analysis based on data in the European Blood and Marrow Transplantation registry. Haematologica. 2008;93:1837-1842.
21. Buadi F, Micallef I, Ansell S, et al. Autologous hematopoietic stem cell transplantation for older patients with relapsed non-Hodgkin lymphoma. Bone Marrow Transplant. 2006;37:1017-1022.
22. Jantunen E, Itala M, Juvonen E, et al. Autologous stem cell transplantation in elderly (>60 years) patients with non-Hodgkin lymphoma: a nation-wide analysis. Bone Marrow Transplant. 2006;37:367-372.
23. Lazarus HM, Zhang M-J, Carreras J, et al. A comparison of HLA-identical sibling allogeneic versus autologous transplantation for diffuse large B-cell lymphoma: A report from the CIBMTR. Biol Blood Marrow Transplant. 2010;16:35-45.
24. Aksentijevich I, Jones R, Ambinder R, Garrett-Mayer E, Flinn I. Clinical outcome following autologous and allogeneic blood and marrow transplantation for relapsed diffuse large-cell non-Hodgkin lymphoma. Biol Blood Marrow Transplant. 2006;12: 965-972.
25. Vose JM, Sharp G, Chan WC, et al. Autologous transplantation for aggressive non-Hodgkin lymphoma: Results of a randomized trial evaluating graft source and minimal residual disease. J Clin Oncol. 2002;20:2344-2352.
26. Haioun C, Mounier N, Emile JF, et al. Rituximab versus observation after high-dose consolidative first-line chemotherapy with autologous stem-cell transplantation in patients with poor-risk diffuse large B-cell lymphoma. Ann Oncol. 2009;20: 1985-1992.
27. van Imhoff GW, van der Holt B, MacKenzie MA, et al. Impact of three courses of intensifiedCHOPprior to high-dose sequential therapy followed by autologous stem-cell transplantation as first-line treatment in poor-risk, aggressive non-Hodgkin lymphoma: comparative analysis of Dutch-Belgian Hemato-Oncology Cooperative Group Studies 27 and 40. J Clin Oncol. 2005;23:3793-3801.
28. Rodriguez R, Nademanee A, Ruel N, et al. Comparison of reduced-intensity and conventional myeloablative regimens for allogeneic transplantation in non-Hodgkin lymphoma. Biol Blood Marrow Transplant. 2006;12:1326-1334.
29. Trneny M, Bosly A, Bouabdallah K, et al. Independent predictive value of PET-CT pre-transplant in relapsed and refractory patients with CD20 diffuse large B-cell lymphoma (DLBCL) Included in the CORAL study. ASH Annual Meet Abstr. 2009; 114:881.
30. Gisselbrecht C, Glass B, Mounier N, et al. R-ICE versus R-DHAP in relapsed patients with CD20 diffuse large B-cell lymphoma (DLBCL) followed by autologous stem cell transplantation: CORAL study. J Clin Oncol. 2009;27:8509.
31. Mounier N, Gisselbrecht C, Fitoussi O, et al. Benefit of rituximab combined to ACVBP (R-ACVBP) over ACVBP in 209 poor-risk BDLCNHLpatients treated with up-front consolidative autotransplantation: a GELA phase II trial (LNH 2003-3). J Clin Oncol. 2009;27:8507.
32. Vellenga E, van Putten WLJ, van't Veer MB, et al. Rituximab improves the treatment results of DHAP-VIM-DHAP and ASCT in relapsed/progressive aggressive CD201 NHL: a prospective randomized HOVON trial. Blood. 2008;111:537-543.
33. Martin A, Conde E, Arnan M, et al. R-ESHAP as salvage therapy for patients with relapsed or refractory diffuse large B-cell lymphoma: the influence of prior exposure to rituximab on outcome. A GEL-TAMO study. Haematologica. 2008;93:1829-1836.
34. Vitolo U, Chiappella A, Angelucci E, et al. Dose-dense and high-dose chemotherapy plus rituximab with autologous stem cell transplantation for primary treatment of diffuse large B-cell lymphoma at poor prognosis: a phase II multicenter study. Haematologica. 2009;94:1250-1258.
35. Fenske TS, Hari PN, Carreras J, et al. Impact of pre-transplant rituximab on survival after autologous hematopoietic stem cell transplantation for diffuse large B cell lymphoma. Biol Blood Marrow Transplant. 2009;15:1455-1464.
36. Kewalramani T, Zelenetz AD, Nimer SD, et al. Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma. Blood. 2004;103:3684-3688.
37. Han L, Zhou J, Hirose T, et al. Feasibility and efficacy of highdose melphalan, cyclophosphamide, etoposide, and dexamethasone (LEED) chemotherapy with or without rituximab followed by autologous stem cell transplantation for aggressive and relapsed non-Hodgkin lymphoma. Int J Hematol. 2006;84: 174-181.
38. Khouri IF, Saliba RM, Hosing C, et al. Concurrent administration of high-dose rituximab before and after autologous stemcell transplantation for relapsed aggressive B-cell non-Hodgkin lymphomas. J Clin Oncol. 2005;23:2240-2247.
39. Tarella C, Zanni M, Magni M, et al. Rituximab improves the efficacy of high-dose chemotherapy with autograft for highrisk follicular and diffuse large B-cell lymphoma: A multicenter Gruppo Italiano Terapie Innnovative nei Linfomi survey. J Clin Oncol. 2008;26:3166-3175.
40. Kamezaki K, Kikushige Y, Numata A, et al. Rituximab does not compromise the mobilization and engraftment of autologous peripheral blood stem cells in diffuse large B-cell lymphoma. Bone Marrow Transplant. 2007;39:523-527.
41. Holtan SG, Porrata LF, Inwards DJ, et al. Timing of autologous stem cell transplantation from last chemotherapy affects lymphocyte collection and survival in non-Hodgkin lymphoma. Br J Haematol. 2006;133:628-633.
42. Damon L, Damon LE, Gaensler K, et al. Impact of intensive PBSC mobilization therapy on outcomes following auto-SCT for non-Hodgkin lymphoma. Bone Marrow Transplant. 2008; 42:649-657.
43. Aggarwal C, Gupta S, Vaughan WP, et al. Improved outcomes in intermediate- and high-risk aggressive non-Hodgkin lymphoma after autologous hematopoietic stem cell transplantation substituting intravenous for oral busulfan in a busulfan, cyclophosphamide, and etoposide preparative regimen. Biol Blood Marrow Transplant. 2006;12:770-777.
44. Tarella C, Zanni M, Di Nicola M, et al. Prolonged survival in poor-risk diffuse large B-cell lymphoma following front-line treatment with rituximab-supplemented, early-intensified chemotherapy with multiple autologous hematopoietic stem cell support: a multicenter study by GITIL (Gruppo Italiano Terapie Innovative nei Linfomi). Leukemia. 2007;21:1802-1811.
45. Glass B, Kloess M, Bentz M, et al. Dose-escalated CHOP plus etoposide (MegaCHOEP) followed by repeated stem cell transplantation for primary treatment of aggressive high-risk non-Hodgkin lymphoma. Blood. 2006;107:3058-3064.
46. Coso D, Sebban C, Boulat O, et al. A phase II trial of rituximab as adjuvant to intensive sequential chemotherapy in patients under 60 years with untreated poor-prognosis diffuse large B-cell lymphoma. Bone Marrow Transplant. 2006;38:217-222.
47. HaiounC, MounierN, QuesnelB, et al. Tandem autotransplant as first-line consolidative treatment in poor-risk aggressive lymphoma: Apilot study of 36 patients. Ann Oncol. 2001;12:1749-1755.
48. Haioun C, Gisselbrecht C, Quesnel B, Morel P, Reyes F. Double autotransplant (DAT) as first-line consolidative treatment in poor-risk aggressive lymphoma: A pilot study of 31 patients [abstract]. Bone Marrow Transplant. 1998;21(Suppl 1):S174.
49. Mounier N, Gisselbrecht C, Briere J, et al. Prognostic factors in patients with aggressive non-Hodgkin lymphoma treated by front-line autotransplantation after complete remission: A cohort study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol. 2004;22:2826-2834.
50. Arranz R, Conde E, Grande C, et al. Dose-escalated CHOP and tailored intensification with IFE according to early response and followed by BEAM/autologous stem-cell transplantation in poor-risk aggressive B-cell lymphoma: a prospective study from theGEL-TAMOStudy Group. Eur JHaematol. 2008;80:227-235.
51. Caballero MD, Perez-Simon JA, Iriondo A, et al. High-dose therapy in diffuse large cell lymphoma: results and prognostic factors in 452 patients from the GEL-TAMO Spanish Cooperative Group. Ann Oncol. 2003;14:140-151.
52. Papajik T, Raida L, Faber E, et al. High-dose therapy and autologous stem cell transplantation in patients with diffuse large B-cell lymphoma in first complete or partial remission. Neoplasma. 2008;55:215-221.
53. Stewart DA, Bahlis N, Valentine K, et al. Upfront double highdose chemotherapy with DICEP followed by BEAM and autologous stem cell transplantation for poor-prognosis aggressive non-Hodgkin lymphoma. Blood. 2006;107:4623-4627.
54. Vranovsky A, Ladicka M, Lakota J. Autologous stem cell transplantation in first-line treatment of high-risk aggressive non-Hodgkin lymphoma. Neoplasma. 2008;55:107-112.
55. Bertz H, Zeiser R, Lange W, et al. Long-term follow-up after high-dose chemotherapy and autologous stem-cell transplantation for high-grade B-cell lymphoma suggests an improved outcome for high-risk patients with respect to the age-adjusted International Prognostic Index. Ann Oncol. 2004;15:1419-1424.
56. Benjamin JE, Chen GL, Cao TM, et al. Long-term follow-up of patients with diffuse large B-cell non-Hodgkin's lymphoma receiving purged autografts after induction failure. Bone Marrow Transplant. 2009;45:303-309.
57. Cortelazzo S, Rambaldi A, Rossi A, et al. Intensification of salvage treatment with high-dose sequential chemotherapy improves the outcome of patients with refractory or relapsed aggressive non-Hodgkin lymphoma. Br J Haematol. 2001;114:333-341.
58. Robertson MJ, Abonour R, Hromas R, et al. Augmented highdose regimen of cyclophosphamide, carmustine, and etoposide with autologous hematopoietic stem cell transplantation for relapsed and refractory aggressive non-Hodgkin lymphoma. Leuk Lymphoma. 2005;46:1477-1487.
59. Josting A, Sieniawski M, Glossmann JP, et al. High-dose sequential chemotherapy followed by autologous stem cell transplantation in relapsed and refractory aggressive non-Hodgkin lymphoma: results of a multicenter phase II study. Ann Oncol. 2005;16:1359-1365.
60. Alousi A, Saliba R, Okoroji G, et al. Disease staging with positron emission tomography or gallium scanning and use of rituximab predict outcome for patients with diffuse large B-cell lymphoma treated with autologous stem cell transplantation. Br J Haematol. 2008;142:786-792.
61. Horwitz SM, Negrin RS, Blume KG, et al. Rituximab as adjuvant to high-dose therapy and autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphoma. Blood. 2004;103:777-783.
62. Hoppe BS, Moskowitz CH, Filippa DA, et al. Involved-field radiotherapy before high-dose therapy and autologous stem-cell rescue in diffuse large-cell lymphoma: long-term disease control and toxicity. J Clin Oncol. 2008;26:1858-1864.
63. Vose JM, Rizzo DJ, Tao-Wu J, et al. Autologous transplantation for diffuse aggressive Non-Hodgkin lymphoma in first relapse or second remission. Biol Blood Marrow Transplant. 2004;10: 116-127.
64. Vose JM, Zhang M-J, Rowlings PA, et al. Autologous transplantation for diffuse aggressive non-Hodgkin lymphoma in patients never achieving remission: A report from the Autologous Blood and Marrow Transplant Registry. J Clin Oncol. 2001;19: 406-413.
65. Rodriguez J, Caballero MD, Gutierrez A, et al. Autologous stem-cell transplantation in diffuse large B-cell non-Hodgkin lymphoma not achieving complete response after induction chemotherapy: the GEL-TAMO experience. Ann Oncol. 2004;15: 1504-1509.
66. Lerner RE, Thomas W, DeFor TE, Weisdorf DJ, Burns LJ. The International Prognostic Index assessed at relapse predicts outcomes of autologous transplantation for diffuse large-cell non-Hodgkin lymphoma in second complete or partial remission. Biol Blood Marrow Transplant. 2007;13:486-492.
67. Sohn BS, Park I, Kim EK, et al. Comparison of clinical outcome after autologous stem cell transplantation between patients with peripheral T-cell lymphomas and diffuse large B-cell lymphoma. Bone Marrow Transplant. 2009.
68. Hamlin PA, Zelenetz AD, Kewalramani T, et al. Age-adjusted International Prognostic Index predicts autologous stem cell transplantation outcome for patients with relapsed or primary refractory diffuse large B-cell lymphoma. Blood. 2003;102: 1989-1996.
69. Kuruvilla J, Pintilie M, Tsang R, et al. Salvage chemotherapy and autologous stem cell transplantation are inferior for relapsed or refractory primary mediastinal large B-cell lymphoma compared with diffuse large B-cell lymphoma. Leuk Lymphoma. 2008;49:1329-1336.
70. Song KW, Mollee P, Keating A, Crump M. Autologous stem cell transplant for relapsed and refractory peripheral T-cell lymphoma: variable outcome according to pathological subtype. Br J Haematol. 2003;120:978-985.
71. Kewalramani T, Zelenetz A, Teruya-Feldstein J, et al. Autologous transplantation for relapsed or primary refractory peripheral T-cell lymphoma. Br J Haematol. 2006;134: 202-207.
72. McCoy AG, Smith EP, Atkinson ME, et al. A novel preparative regimen for autologous transplant in non-Hodgkin lymphoma: Long-term experience with etoposide and thiotepa. Bone Marrow Transplant. 2004;33:19-24.
73. Usui N, Yano S, Asai O, et al. Long-term follow-up high-dose chemotherapy (drug-only program) followed by autologous stem cell transplantation for aggressive non-Hodgkin lymphomas. Clin Lymphoma Myeloma. 2005;6:31-36.
74. Smith SD, Bolwell BJ, Advani AS, et al. High rate of survival in transformed lymphoma after autologous stem cell transplant: pathologic analysis and comparison with de novo diffuse large B-cell lymphoma. Leuk Lymphoma. 2009;50:1625-1631.
75. Escalon MP, Stefanovic A, Venkatraman A, et al. Autologous transplantation for relapsed non-Hodgkin lymphoma using intravenous busulfan and cyclophosphamide as conditioning regimen: A single center experience. Bone Marrow Transplant. 2009; 44:89-96.
76. Mey U, Jha V, Strehl J, et al. High dose chemotherapy with autologous stem cell transplantation in diffuse large B-cell lymphoma. GMS Ger Med Sci. 2007;5. Doc02.
77. Waheed F, Kancherla R, Seiter K, et al. High dose chemotherapy with thiotepa, mitoxantrone and carboplatin (TMJ) followed by autologous stem cell support in 100 consecutive lymphoma patients in a single centre: analysis of efficacy, toxicity and prognostic factors. Leuk Lymphoma. 2004;45:2253-2259.
78. Doocey RT, Toze CL, Connors JM, et al. Allogeneic haematopoietic stem-cell transplantation for relapsed and refractory aggressive histology non-Hodgkin lymphoma. Br J Haematol. 2005;131:223-230.
79. Sirvent A, Dhedin N, Michallet M, et al. Low nonrelapse mortality and prolonged long-term survival after reduced-intensity allogeneic stem cell transplantation for relapsed or refractory diffuse large B cell lymphoma: report of the Société Française de Greffe de Moelle et de Thérapie Cellulaire. Biol Blood Marrow Transplant. 2009;16:78-85.
80. Kusumi E, Kami M, Kanda Y, et al. Reduced-intensity hematopoietic stem-cell transplantation for malignant lymphoma: a retrospective survey of 112 adult patients in Japan. Bone Marrow Transplant. 2005;36:205-213.
81. Thomson KJ, Morris EC, Bloor A, et al. Favorable long-term survival after reduced-intensity allogeneic transplantation for multiple-relapse aggressive non-Hodgkin lymphoma. J Clin Oncol. 2009;27:426-432.
82. Rezvani A, Norasetthada L, Gooley T, et al. Non-myeloablative allogeneic haematopoietic cell transplantation for relapsed diffuse large B-cell lymphoma: a multicentre experience. Br J Haematol. 2008;143:395-403.